According to a large nationwide cohort study published in JAMA Network Open, prenatal COVID-19 exposure has not been linked to a broad increase in neurodevelopmental or neurological disorders among children. Researchers analyzing data from Norway found that while most outcomes showed no elevated risk, a sensitivity analysis focused on the early pandemic identified a heightened risk of developmental speech or language disorders.
Nationwide Registry Design Tracks Numerous Births
The cohort study evaluated all children born in Norway between March 2020 and December 2023, requiring at least 22 completed gestational weeks and a birth weight above 500 grams, according to registry data. Investigators utilized national health registries to track maternal backgrounds, birth characteristics, prenatal SARS-CoV-2 exposure confirmed by positive PCR tests between conception and delivery, and subsequent medical diagnoses.
Maria C. Magnus and colleagues at the Norwegian Institute of Public Health examined eight distinct outcomes using Cox proportional hazards regression. The assessed conditions included any neurodevelopmental disorder, autism, developmental speech or language disorders, motor disorders, intellectual disorders, any neurological disorder, epilepsy, and sensory impairments.
Exposed Cohort Shows No Broad Risk Across Most Outcomes
Out of 204,663 children included in the analysis—51.2% of whom were male—16,325 children, or 8.0%, experienced prenatal exposure to maternal COVID-19. According to the study findings, exposed children showed no increased risk for any neurodevelopmental disorder, yielding an adjusted hazard ratio of 0.97 with a 95% confidence interval ranging from 0.88 to 1.08.
Specific condition categories yielded similar figures. Autism showed an adjusted hazard ratio of 0.88 (95% CI, 0.67 to 1.15), while speech or language disorders registered at 1.13 (95% CI, 0.80 to 1.59). Motor disorders stood at 0.83 (95% CI, 0.44 to 1.56), and intellectual disorders recorded 1.19 (95% CI, 0.65 to 2.19). Neurological endpoints remained equally stable, with any neurological disorder at 0.97 (95% CI, 0.88 to 1.07), epilepsy at 1.14 (95% CI, 0.87 to 1.48), and sensory impairments at 1.09 (95% CI, 0.92 to 1.30).
Did you know? The study population encompassed every registered birth in Norway over a nearly four-year span from March 2020 through December 2023, capturing numerous total infants.
Early Pandemic Sensitivity Analysis Identifies Speech Signal
A secondary sensitivity analysis restricted to children born before the end of March 2022 was designed to limit misclassification tied to reduced testing availability later in the pandemic. Within this early-exposure subset, researchers identified an increased risk of speech or language disorders among exposed children, with an adjusted hazard ratio of 2.22 (95% CI, 1.44 to 3.41).
Study authors emphasize that because this signal emerged from a single sensitivity analysis, replication in other populations is necessary before it can influence clinical monitoring or guidelines. The primary findings offer broad reassurance that prenatal exposure does not generally elevate the risk of neurological or neurodevelopmental conditions.
Frequently Asked Questions
Did prenatal COVID-19 exposure increase the overall risk of neurodevelopmental disorders?
What specific outcome showed a potential risk in the study?
A sensitivity analysis restricted to the early phase of the pandemic identified an increased risk of developmental speech or language disorders among exposed children.
How many children were included in the research?
The study evaluated 204,663 children born in Norway between March 2020 and December 2023, of whom 16,325 had prenatal exposure to maternal COVID-19.
If you found this breakdown informative, share your thoughts in the comments below, explore our latest health research coverage, or subscribe to our newsletter for ongoing updates.
Related reading